United States Immune Thrombocytopenia Treatment Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Immune Thrombocytopenia Treatment Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Immune Thrombocytopenia Treatment Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Immune Thrombocytopenia Treatment Overall Market Size
2.1 United States Immune Thrombocytopenia Treatment Market Size: 2021 VS 2027
2.2 United States Immune Thrombocytopenia Treatment Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Immune Thrombocytopenia Treatment Players in United States Market
3.2 Top United States Immune Thrombocytopenia Treatment Companies Ranked by Revenue
3.3 United States Immune Thrombocytopenia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Immune Thrombocytopenia Treatment Companies in United States Market, by Revenue in 2020
3.5 Companies Immune Thrombocytopenia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Immune Thrombocytopenia Treatment Players in United States Market
3.6.1 List of Tier 1 Immune Thrombocytopenia Treatment Companies in United States
3.6.2 List of Tier 2 and Tier 3 Immune Thrombocytopenia Treatment Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Immune Thrombocytopenia Treatment Market Size Markets, 2021 & 2027
4.1.2 Corticosteroids
4.1.3 Intravenous Immunoglobulin (IVIG)
4.1.4 Anti-D Immunoglobulin
4.1.5 Thrombopoietin Receptor Agonist (TPO-RA)
4.1.6 Others
4.2 By Type - United States Immune Thrombocytopenia Treatment Revenue & Forecasts
4.2.1 By Type - United States Immune Thrombocytopenia Treatment Revenue, 2016-2021
4.2.2 By Type - United States Immune Thrombocytopenia Treatment Revenue, 2022-2027
4.2.3 By Type - United States Immune Thrombocytopenia Treatment Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Immune Thrombocytopenia Treatment Market Size, 2021 & 2027
5.1.2 Hospitals and Clinics
5.1.3 Research and Academic Institutes
5.1.4 Others
5.2 By Application - United States Immune Thrombocytopenia Treatment Revenue & Forecasts
5.2.1 By Application - United States Immune Thrombocytopenia Treatment Revenue, 2016-2021
5.2.2 By Application - United States Immune Thrombocytopenia Treatment Revenue, 2022-2027
5.2.3 By Application - United States Immune Thrombocytopenia Treatment Revenue Market Share, 2016-2027
6 Immune Thrombocytopenia Treatment Companies Profiles
6.1 CSL Behring
6.1.1 CSL Behring Company Details
6.1.2 CSL Behring Business Overview
6.1.3 CSL Behring Immune Thrombocytopenia Treatment Introduction
6.1.4 CSL Behring Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.1.5 CSL Behring Recent Developments
6.2 Amgen
6.2.1 Amgen Company Details
6.2.2 Amgen Business Overview
6.2.3 Amgen Immune Thrombocytopenia Treatment Introduction
6.2.4 Amgen Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.2.5 Amgen Recent Developments
6.3 F.Hoffmann-La Roche
6.3.1 F.Hoffmann-La Roche Company Details
6.3.2 F.Hoffmann-La Roche Business Overview
6.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Introduction
6.3.4 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.3.5 F.Hoffmann-La Roche Recent Developments
6.4 Kyowa Hakko Kirin
6.4.1 Kyowa Hakko Kirin Company Details
6.4.2 Kyowa Hakko Kirin Business Overview
6.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Introduction
6.4.4 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.4.5 Kyowa Hakko Kirin Recent Developments
6.5 Rigel Pharmaceuticals
6.5.1 Rigel Pharmaceuticals Company Details
6.5.2 Rigel Pharmaceuticals Business Overview
6.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
6.5.4 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.5.5 Rigel Pharmaceuticals Recent Developments
6.6 Shionogi
6.6.1 Shionogi Company Details
6.6.2 Shionogi Business Overview
6.6.3 Shionogi Immune Thrombocytopenia Treatment Introduction
6.6.4 Shionogi Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.6.5 Shionogi Recent Developments
6.7 Dova Pharmaceuticals
6.7.1 Dova Pharmaceuticals Company Details
6.7.2 Dova Pharmaceuticals Business Overview
6.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
6.7.4 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.7.5 Dova Pharmaceuticals Recent Developments
6.8 Novartis
6.8.1 Novartis Company Details
6.8.2 Novartis Business Overview
6.8.3 Novartis Immune Thrombocytopenia Treatment Introduction
6.8.4 Novartis Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.8.5 Novartis Recent Developments
6.9 Shire
6.9.1 Shire Company Details
6.9.2 Shire Business Overview
6.9.3 Shire Immune Thrombocytopenia Treatment Introduction
6.9.4 Shire Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.9.5 Shire Recent Developments
6.10 Ligand Pharmaceuticals
6.10.1 Ligand Pharmaceuticals Company Details
6.10.2 Ligand Pharmaceuticals Business Overview
6.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
6.10.4 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.10.5 Ligand Pharmaceuticals Recent Developments
6.11 GSK
6.11.1 GSK Company Details
6.11.2 GSK Business Overview
6.11.3 GSK Immune Thrombocytopenia Treatment Introduction
6.11.4 GSK Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.11.5 GSK Recent Developments
6.12 Grifols Biologicals
6.12.1 Grifols Biologicals Company Details
6.12.2 Grifols Biologicals Business Overview
6.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Introduction
6.12.4 Grifols Biologicals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.12.5 Grifols Biologicals Recent Developments
6.13 Jiangsu Hengrui Pharmaceutical
6.13.1 Jiangsu Hengrui Pharmaceutical Company Details
6.13.2 Jiangsu Hengrui Pharmaceutical Business Overview
6.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Introduction
6.13.4 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021)
6.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. Immune Thrombocytopenia Treatment Market Opportunities & Trends in United States Market
Table 2. Immune Thrombocytopenia Treatment Market Drivers in United States Market
Table 3. Immune Thrombocytopenia Treatment Market Restraints in United States Market
Table 4. Key Players of Immune Thrombocytopenia Treatment in United States Market
Table 5. Top Immune Thrombocytopenia Treatment Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Immune Thrombocytopenia Treatment Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Immune Thrombocytopenia Treatment Revenue Share by Companies, 2016-2021
Table 8. Companies Immune Thrombocytopenia Treatment Product Type
Table 9. List of Tier 1 Immune Thrombocytopenia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Immune Thrombocytopenia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - United States Immune Thrombocytopenia Treatment Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Immune Thrombocytopenia Treatment Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Immune Thrombocytopenia Treatment Revenue (US$, Mn), 2022-2027
Table 14. By Application - United States Immune Thrombocytopenia Treatment Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Immune Thrombocytopenia Treatment Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Immune Thrombocytopenia Treatment Revenue (US$, Mn), 2022-2027
Table 17. CSL Behring Company Details
Table 18. CSL Behring Business Overview
Table 19. CSL Behring Immune Thrombocytopenia Treatment Product
Table 20. CSL Behring Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. CSL Behring Recent Developments
Table 22. Amgen Company Details
Table 23. Amgen Business Overview
Table 24. Amgen Immune Thrombocytopenia Treatment Product
Table 25. Amgen Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Amgen Recent Developments
Table 27. F.Hoffmann-La Roche Company Details
Table 28. F.Hoffmann-La Roche Business Overview
Table 29. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product
Table 30. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. F.Hoffmann-La Roche Recent Developments
Table 32. Kyowa Hakko Kirin Company Details
Table 33. Kyowa Hakko Kirin Business Overview
Table 34. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product
Table 35. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. Kyowa Hakko Kirin Recent Developments
Table 37. Rigel Pharmaceuticals Company Details
Table 38. Rigel Pharmaceuticals Business Overview
Table 39. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 40. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Rigel Pharmaceuticals Recent Developments
Table 42. Shionogi Company Details
Table 43. Shionogi Business Overview
Table 44. Shionogi Immune Thrombocytopenia Treatment Product
Table 45. Shionogi Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. Shionogi Recent Developments
Table 47. Dova Pharmaceuticals Company Details
Table 48. Dova Pharmaceuticals Business Overview
Table 49. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 50. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. Dova Pharmaceuticals Recent Developments
Table 52. Novartis Company Details
Table 53. Novartis Business Overview
Table 54. Novartis Immune Thrombocytopenia Treatment Product
Table 55. Novartis Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Novartis Recent Developments
Table 57. Shire Company Details
Table 58. Shire Business Overview
Table 59. Shire Immune Thrombocytopenia Treatment Product
Table 60. Shire Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 61. Shire Recent Developments
Table 62. Ligand Pharmaceuticals Company Details
Table 63. Ligand Pharmaceuticals Business Overview
Table 64. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 65. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 66. Ligand Pharmaceuticals Recent Developments
Table 67. GSK Company Details
Table 68. GSK Business Overview
Table 69. GSK Immune Thrombocytopenia Treatment Product
Table 70. GSK Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 71. GSK Recent Developments
Table 72. Grifols Biologicals Company Details
Table 73. Grifols Biologicals Business Overview
Table 74. Grifols Biologicals Immune Thrombocytopenia Treatment Product
Table 75. Grifols Biologicals Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 76. Grifols Biologicals Recent Developments
Table 77. Jiangsu Hengrui Pharmaceutical Company Details
Table 78. Jiangsu Hengrui Pharmaceutical Business Overview
Table 79. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product
Table 80. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue in United States Market (2016-2021) & (US$ Million)
Table 81. Jiangsu Hengrui Pharmaceutical Recent Developments
List of FiguresFigure 1. Immune Thrombocytopenia Treatment Segment by Type
Figure 2. Immune Thrombocytopenia Treatment Segment by Application
Figure 3. United States Immune Thrombocytopenia Treatment Market Overview: 2020
Figure 4. United States Immune Thrombocytopenia Treatment Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Immune Thrombocytopenia Treatment Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Immune Thrombocytopenia Treatment Revenue in 2020
Figure 7. By Type - United States Immune Thrombocytopenia Treatment Revenue Market Share, 2016-2027
Figure 8. By Application - United States Immune Thrombocytopenia Treatment Revenue Market Share, 2016-2027
Figure 9. CSL Behring Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Amgen Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Shionogi Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Novartis Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 17. Shire Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 18. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 19. GSK Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 20. Grifols Biologicals Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 21. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)